# Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

> **NCT01775124** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 332 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01775124
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-22
- **Primary completion:** 2015-11-23
- **Final completion:** 2015-11-23
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01775124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01775124, "Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01775124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*